Browse News
Filter News
Found 2,027 articles
-
Emmaus Life Sciences Provides Interim Sales Information
7/22/2021
Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment, announced preliminary sales results for the six months ended June 30, 2021.
-
Blueprint Medicines to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021
7/22/2021
Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday , July 29, 2021 to report its second quarter 2021 financial results and provide a corporate update.
-
OnKure Builds its Discovery Team and Appoints Heads of Computational Drug Discovery and Pharmacology
7/20/2021
OnKure, Inc. announced the appointment of two key members to its drug discovery team, James Blake, Ph.D., Senior Vice President of Computational Drug Discovery, and Richard Woessner, Ph.D., Senior Vice President of Pharmacology.
-
Emmaus Life Sciences Announces Submission of Endari® Marketing Authorization Application in Kuwait
7/15/2021
Emmaus Life Sciences, Inc. announced today the submission of its application for Marketing Authorization (MA) for Endari® to the Kuwait Drug and Food Control (KDFC).
-
Batavia Biosciences successfully manufactures IAVI’s Lassa fever vaccine candidate on innovative HIP-Vax platform to support Phase I clinical trials
7/14/2021
Batavia Biosciences announces today that they have successfully produced vaccine material for a Phase I clinical trial of IAVI’s Lassa fever vaccine candidate, rVSV∆G-LASV-GPC.
-
Castor Raises $45M Series B to Modernize the Clinical Trial Process and Maximize the Impact of Research Data on Patient Lives
7/14/2021
Castor, a leading provider of clinical trial software, announced today the closing of a $45 million Series B financing round, bringing the company’s total funding to $65 million.
-
Stryker Introduces Market-Leading Tornier Shoulder Arthroplasty Portfolio and Launches New Tornier Perform™ Humeral System
7/13/2021
Stryker, one of the world’s leading medical technology companies, has officially introduced the Tornier shoulder arthroplasty portfolio and launched its first new Tornier product, the Perform™ Humeral Stem.
-
Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant
7/12/2021
Texas Biomedical Research Institute and Aridis' data confirmed AR-712 binds to and neutralizes the Delta variant of SARS-CoV-2 virus
-
New Clinical Study Investigates Using Integrated Diagnostics to Enable Precision Medicine for Liver Cancer Patients
7/9/2021
Perspectum is pleased to announce that a new prospective, observational, cohort study called Precision medicine for liver tumours with quantitative magnetic resonance imaging and whole genome sequencing is underway.
-
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 07, 2021
7/7/2021
Blueprint Medicines Corporation announced that, effective on July 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 25,762 shares of its common stock and an aggregate of 12,880 restricted stock units to 12 new employees under Blueprint Medicines' 2020 Inducement Plan.
-
BioSpace Movers & Shakers, June 25
6/25/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Next-Generation Sequencing (NGS) Services Market: Overview, Segmentation & Regional Outlook
6/24/2021
DNA comprises the blueprints of life. Within the structure of DNA, there are codes which are required for the assembly of proteins and non-coding RNA; these molecular machineries are responsible for affecting the biological systems that are creating and maintaining life.
-
Implantable Brain Device Relieves Pain in Early Study
6/21/2021
A computerized brain implant effectively relieves short-term and chronic pain in rodents, a new study finds.
-
Cluster Headache Syndrome Market: Increasing Global Geriatric Population to Drive the Market
6/18/2021
The global cluster headache syndrome market is foreseen to be advantaged by the advent of new medical equipment and drugs for treatment.
-
The U.S. FDA approved Ayvakit for the treatment of adult patients with advanced sytematic mastocytosis (SM), advanced SM, and mast cell leukemia.
-
Collegium Announces Publication of Real-World Data in Journal of Pain Research
6/16/2021
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced a publication titled, “Nonmedical Use of Xtampza® ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment: Real-world Data from the Addiction Severity Index – Multimedia Version (ASI-MV®),”
-
FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis
6/16/2021
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT™ (avapritinib) for the treatment of adult patients with advanced systemic mastocytosis (Advanced SM), including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN) and mast cell leukemia (MCL).
-
EDCTP and CEPI Funding Moves IAVI's Lassa fever Vaccine Candidate Into Advanced Clinical Development
6/15/2021
IAVI has received an award of €22.8 million from the European & Developing Countries Clinical Trials Partnership (EDCTP) and the Coalition for Epidemic Preparedness Innovations (CEPI) to conduct a Phase IIb clinical trial of a novel vaccine candidate to prevent Lassa fever disease.
-
Caris Life Sciences and Elevation Oncology Announce Joint Discovery and Development Collaboration Focused on Oncogenic Fusions and Driver Mutations
6/15/2021
Caris Life Sciences® and Elevation Oncology announced a strategic collaboration to jointly identify oncogenic fusions and mutations that are driver alterations.
-
The month of June continues to be busy for the U.S. Food and Drug Administration. There are three PDUFA dates on the calendar for this week. Here’s a look.